Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives

We continue to develop relationships with potential future development partners such as larger global pharmaceutical companies, regional companies and peer mid-cap companies. 

Building on our semi-virtual business model, skilled and experienced strategic and technical specialists will be added to the team in accordance with need as the Company grows. 

Clinical Development: Active forward planning for Part B of the XanaMIA trial following the Part A results release. Ancillary clinical pharmacology studies planned. Long term clinical program designs for AD, MDD, FXS and other potential indications under regular review.

Regulatory nonclinical studies: Plan and conduct essential Good Laboratory Practice (regulatory) non-clinical studies. 

Manufacturing: Explore manufacturing process improvements and scale-up work. Additional Good Manufacturing Practices (GMP) production batches to be produced to support smooth transition into later stage clinical development, ensuring that to-be-marketed Xanamem drug substance and drug product are used in pivotal, registration-enabling studies.